Free Trial
NASDAQ:ANNX

Annexon Q1 2025 Earnings Report

Annexon logo
$2.32 -0.02 (-0.85%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.31 -0.01 (-0.65%)
As of 07/18/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annexon Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
12:30PM ET

Upcoming Earnings

Annexon's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Annexon Earnings Headlines

Annexon: Lead GBS Therapy Stokes Near-Term Potential
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Annexon Sees Unusually Large Options Volume (NASDAQ:ANNX)
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX) Inc. is a clinical-stage biotechnology company dedicated to developing treatments that target the complement system, a key component of the immune response implicated in a range of neurodegenerative and neuroinflammatory disorders. The company’s lead assets are monoclonal antibodies designed to inhibit specific complement proteins, with the goal of preventing or mitigating tissue damage caused by aberrant complement activation. Annexon’s research focuses on conditions such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis and Parkinson’s disease.

The company’s pipeline is anchored by ANX005, an antibody that binds to C1q and blocks activation of the classical complement cascade. ANX005 has completed Phase 2 studies in neuromuscular indications and is being explored in additional neurodegenerative settings. Annexon’s second clinical candidate, ANX007, inhibits C1q-mediated synapse loss, and is currently under investigation for diseases characterized by synaptic dysfunction. Together, these programs represent a differentiated approach to modulating complement biology in both peripheral and central nervous system disorders.

Founded in 2015 by a team of scientists and executives with deep expertise in immunology and neuroscience, Annexon is headquartered in South San Francisco. The company was built on foundational research linking complement activation to neuronal injury, and it has since forged collaborations with leading academic and industry partners to support its drug development strategy. Leadership is led by President and Chief Executive Officer Brett Monia, Ph.D., whose prior experience includes senior roles at Ionis Pharmaceuticals and Alnylam, and Chief Scientific Officer Kirlos Dhillon, M.D., who has overseen early-stage research in complement-targeted therapies.

Annexon conducts its clinical trials across North America and Europe, engaging with investigational sites and regulatory authorities in multiple regions. The company’s integrated approach combines in-house research capabilities with external collaborations and licensing agreements to advance its complement inhibition platform. As Annexon advances its programs through clinical development, it aims to address significant unmet medical needs in neurological diseases driven by dysregulated complement activity.

View Annexon Profile

More Earnings Resources from MarketBeat